Literature DB >> 11245352

Multiple dose IVIG treatment in neonatal immune hemolytic jaundice.

G Tanyer1, Z Siklar, Y Dallar, Y Yildirmak, U Tiraş.   

Abstract

Isoimmune hemolytic jaundice due to ABO and Rh blood group incompatibility is an important problem in the neonatal period. Intravenous immune globulin (IVIG) treatment in isoimmune jaundice has been shown to be effective, but the response to treatment is variable. In this study, the effect of multiple doses IVIG therapy versus single dose MG therapy was investigated in 61 babies who had ABO and Rh hemolytic disease. Patients were divided into three groups. Group I received multiple dose IVIG treatment, group II received single dose MG treatment, and group III was not given any IVIG. All three groups received phototherapy. No exchange transfusion was needed in group I. The rate of exchange transfusion was 12 per cent in group II and 33 per cent in group III. Duration of phototherapy was shorter in group I than in groups II and III. It was concluded that IVIG treatment reduces the need of exchange transfusion in neonatal isoimmune hemolytic jaundice by lowering hemolysis. Multiple doses IVIG treatment appears to be better at blocking ongoing hemolysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245352     DOI: 10.1093/tropej/47.1.50

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  6 in total

1.  Intravenous immunoglobulins in rhesus hemolytic disease.

Authors:  Kanya Mukhopadhyay; Srinivas Murki; Anil Narang; Sourabh Dutta
Journal:  Indian J Pediatr       Date:  2003-09       Impact factor: 1.967

2.  Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn--a prospective randomized controlled trial.

Authors:  Mohsen Saleh Elalfy; Nancy Samir Elbarbary; Heba Wegdan Abaza
Journal:  Eur J Pediatr       Date:  2010-10-06       Impact factor: 3.183

3.  Addressing hemolysis in an infant due to mother-infant ABO blood incompatibility.

Authors:  Sandra Martin; Rebecca N Jerome; Marcia I Epelbaum; Annette M Williams; William Walsh
Journal:  J Med Libr Assoc       Date:  2008-07

4.  Single versus multiple dose intravenous immunoglobulin in combination with LED phototherapy in the treatment of ABO hemolytic disease in neonates.

Authors:  Gamze Demirel; Melek Akar; Istemi Han Celik; Omer Erdeve; Nurdan Uras; Serife Suna Oguz; Ugur Dilmen
Journal:  Int J Hematol       Date:  2011-05-25       Impact factor: 2.490

5.  International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn.

Authors:  Lani Lieberman; Enrico Lopriore; Jillian M Baker; Rachel S Bercovitz; Robert D Christensen; Gemma Crighton; Meghan Delaney; Ruchika Goel; Jeanne E Hendrickson; Amy Keir; Denise Landry; Ursula La Rocca; Brigitte Lemyre; Rolf F Maier; Eduardo Muniz-Diaz; Susan Nahirniak; Helen V New; Katerina Pavenski; Maria Cristina Pessoa Dos Santos; Glenn Ramsey; Nadine Shehata
Journal:  Br J Haematol       Date:  2022-04-12       Impact factor: 8.615

Review 6.  Immunoglobulin for alloimmune hemolytic disease in neonates.

Authors:  Carolien Zwiers; Mirjam Ea Scheffer-Rath; Enrico Lopriore; Masja de Haas; Helen G Liley
Journal:  Cochrane Database Syst Rev       Date:  2018-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.